Dissemination and Characteristics of Circulating Tumor Cells in Breast Cancer: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Rita Xu and Version 6 by Rita Xu.

Breast cancer metastasis is the leading cause of cancer deaths in women and is difficult to combat due to the long periods in which disseminated cells stay dormant and can be re-activated to start the relapse. Assessing the number and molecular profile of circulating tumor cells (CTCs) in breast cancer patients, especially in early breast cancer, should help in identifying the possibility of relapse in time for therapeutic intervention to prevent or delay recurrence. Molecular analysis of CTCs have a potential to define particular susceptibilities of the cells representing the current tumor burden, which may be considerably different from the cells of the primary tumor. While metastatic breast cancer is considered incurable this approach may off er more tailored therapy to the patients. In this article we inspect the routes to metastasis in breast cancer and how they can be linked to specific features of CTCs, how CTC analysis may be used in therapy, and what is the current status of the research and efforts to include CTC analysis in clinical practice.

  • CTC
  • breast cancer
  • metastasis
Please wait, diff process is still running!

References

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Christoph Klein; Dieter Hölzel; Systemic Cancer Progression and Tumor Dormancy: Mathematical Models Meet Single Cell Genomics. CAell Cancycler J. Clin. 20018, 68, 394–424.6, 5, 1788-1798, 10.4161/cc.5.16.3097.
  2. Szostakowska, M.; Trebinska-Stryjewska, A.; Grzybowska, E.A.; Fabisiewicz, A; Resistance to endocrine therapy in breast cancer: Molecular mechanisms and future goals. BChristoph Klein; Parallel progression of primary tumours and metastases. Naturea Reviewst Cancer Res. Treat. 20019, 173, 489–497, , 9, 302-312, 10.1038/nrc2627.
  3. Demicheli, R.; Ardoino, I.; Boracchi, P.; Coradini, D.; Agresti, R.; Ferraris, C.; Gennaro, M.; Hrushesky, W.J.; Biganzoli, E. Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer 2010, 10, 656.Bockhorn, M.; Jain, R.K.; Munn, L.L. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol 2007, 8, 444–448, doi:10.1016/S1470-2045(07)70140-7.
  4. Liedtke, C.; Mazouni, C.; Hess, K.R.; Andre, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez-Angulo, A.M.; Hennessy, B.; Green, M.; et al.et al Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J.Judah Folkman; Role of angiogenesis in tumor growth and metastasis. Seminars Clin. Oncol. ogy 2008, 2, 26, 1275–1281, 9, 15-18, 10.1016/s0093-7754(02)70065-1.
  5. Dent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A; et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. CliGerhard Hamilton; Barbara Rath; Circulating Tumor Cells in the Parallel Invasion Model Supporting Early Metastasis. On. Cancer Romedicines. 2007, 118, 3, 4429–4434., 15-27, 10.7150/oncm.22576.
  6. Klein, C.A.; Holzel, D; Systemic cancer progression and tumor dormancy: Mathematical models meet single cell genomics. CKent Hunter; Hosseini H; Obradović Mms; Hoffmann M; Harper Kl; Sosa Ms; Werner-Klein M; Nanduri Lk; Werno C; Ehrl C; Maneck M; Patwary N; Haunschild G; Gužvić M; Reimelt C; Grauvogl M; Eichner N; Weber F; Hartkopf Ad; Taran Fa; Brucker Sy; Fehm T; Rack B; Buchholz S; Spang R; Meister G; Aguirre-Ghiso Ja; Klein Ca; Faculty of 1000 evaluation for Early dissemination seeds metastasis in breast cancer.. F1000 - Post-publication peer review of the biomedicall Cycl lite rature 2006, 17, 5, 1788–1798.40, , 10.3410/f.727099750.793539682.
  7. Klein, C.A; Parallel progression of primary tumours and metastases. Kathryn L. Harper; Maria Soledad Sosa; David Entenberg; Hedayatollah Hosseini; Julie F. Cheung; Rita Nobre; Alvaro Avivar-Valderas; Chandandaneep Nagi; Nomeda Girnius; Roger J. Davis; Eduardo F. Farias; John Condeelis; Christoph A. Klein; Julio A. Aguirre-Ghiso; Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nat. Rurev. Cancer 2009, 9, 302–312.16, 540, 588-592, 10.1038/nature20609.
  8. Bockhorn, M.; Jain, R.K.; Munn, L.L; Active versus passive mechanisms in metastasis: Do cancer cells crawl into vessels, or are they pushed?. LanAnne Bruun Krøigård; Martin J. Larsen; Charlotte Brasch-Andersen; Anne-Vibeke Lænkholm; Ann Knoop; Jeanette Dupont Jensen; Martin Bak; Jan Mollenhauer; Mads Thomassen; Torben A. Kruse; Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence. Sciet Oncol ntific Reports 20017, 8, 444–448, , 7, 43813, 10.1038/srep43813.
  9. Judah Folkman; Role of angiogenesis in tumor growth and metastasis. STuan Zea Tan; Qing Hao Miow; Yoshio Miki; Tetsuo Noda; Seiichi Mori; Ruby Yun-Ju Huang; Jean-Paul Thiery; Epithelial‐mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Moleminculars in Oncology Medicine 2002, 29, 15-18, 10.1016/s0093-7754(02)70065-1.14, 6, 1279-1293, 10.15252/emmm.201404208.
  10. Gerhard Hamilton; Barbara Rath; Circulating Tumor Cells in the Parallel Invasion Model Supporting Early Metastasis. OncomKari R. Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T. C. Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F. Schwabe; Linda T. Vahdat; Nasser K. Altorki; Vivek Mittal; Dingcheng Gao; Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Naturedicine 2018, 3, 15-27, 10.7150/oncm.22576.5, 527, 472-476, 10.1038/nature15748.
  11. Hosseini, H.; Obradovic, M.M.S.; Hoffmann, M.; Harper, K.L.; Sosa, M.S.; Werner-Klein, M.; Nanduri, L.K.; Werno, C.; Ehrl, C.; Maneck, M; et al. Early dissemination seeds metastasis in breast cancer. Xin Ye; Thomas Brabletz; Yibin Kang; Gregory D. Longmore; M Ángela Nieto; Ben Z. Stanger; Jing Yang; Robert A. Weinberg; Upholding a role for EMT in breast cancer metastasis. Nature 2016, 7, 540, 552-558, 10.1038/nature20785.7, E1-E3, 10.1038/nature22816.
  12. Harper, K.L.; Sosa, M.S.; Entenberg, D.; Hosseini, H.; Cheung, J.F.; Nobre, R.; Avivar-Valderas, A.; Nagi, C.; Girnius, N.; Davis, R.J; et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. NatFrank Aw Coumans; Sabine Siesling; Leon Wmm Terstappen; Abstract 1463: Detection of cancer before distant metastasis.. Tumore Biology 2016, 540, 588-592, 10.1038/nature20609.3, 73, 1463-1463, 10.1158/1538-7445.am2013-1463.
  13. Kroigard, A.B.; Larsen, M.J.; Brasch-Andersen, C.; Laenkholm, A.V.; Knoop, A.S.; Jensen, J.D.; Bak, M.; Mollenhauer, J.; Thomassen, M.; Kruse, T.A; et al. Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence. SciC.S. Hall; A. Lucci; Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Brenastific Reports Diseases: A Year Book Quarterly 2017, 7, 43813, 10.1038/srep43813.4, 25, 242-243, 10.1016/j.breastdis.2014.07.040.
  14. Tan, T.Z.; Miow, Q.H.; Miki, Y.; Noda, T.; Mori, S.; Huang, R.Y.; Thiery, J.P; Epithelial‐mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBNicola Aceto; Fluctuating numbers of circulating tumor cells in cancer patients and the meaning of zero counts.. O Mncolecular Medicine target 2014, 6, 1279-1293, 10.15252/emmm.201404208.9, 10, 2658-2659, 10.18632/oncotarget.26850.
  15. Fischer, K.R.; Durrans, A.; Lee, S.; Sheng, J.; Li, F.; Wong, S.T.; Choi, H.; El Rayes, T.; Ryu, S.; Troeger, J; et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. NaMarta Vilalta; Marjan Rafat; Amato J. Giaccia; Edward E. Graves; Recruitment of circulating breast cancer cells is stimulated by radiotherapy.. Cell Reporture s 2015, 527, 472-476, 10.1038/nature15748.4, 8, 402-9, 10.1016/j.celrep.2014.06.011.
  16. Ye, X.; Brabletz, T.; Kang, Y.; Longmore, G.D.; Nieto, M.A.; Stanger, B.Z.; Yang, J.; Weinberg, R.A. Upholding a role for EMT in breast cancer metastasis. Nature 2017, 547, E1–E3.Martin, O.A.; Anderson, R.L.; Narayan, K.; MacManus, M.P. Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? Rev. Clin. Oncol. 2017, 14, 32–44, doi:10.1038/nrclinonc.2016.128.
  17. Frank A. W. Coumans; S. Siesling; Leon W.M.M. Terstappen; Detection of cancer before distant metastasis. Marcus Vetter; Julia Landin; Barbara Maria Szczerba; Francesc Castro-Giner; Sofia Gkountela; Cinzia Donato; Ilona Krol; Ramona Scherrer; Cathrin Balmelli; Alexandra Malinovska; Alfred Zippelius; Christian Kurzeder; Viola Heinzelmann-Schwarz; Walter P. Weber; Christoph Rochlitz; Nicola Aceto; Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer. BMCreast Cancer Research 2013, 13, 283, 10.1186/1471-2407-13-283.8, 20, 141, 10.1186/s13058-018-1067-y.
  18. Peeters, D.J.; van Dam, P.J.; Van den Eynden, G.G.; Rutten, A.; Wuyts, H.; Pouillon, L.; Peeters, M.; Pauwels, P.; Van Laere, S.J.; van Dam, P.A; et al. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. BrJacqueline Shaw; David Guttery; Allison Hills; Daniel Fernandez Garcia; Karen Page; Brenda M. Rosales; Kate S. Goddard; Robert Hastings; Jinli Luo; Olivia Ogle; Laura Woodley; Simak Ali; Justin Stebbing; R. Charles Coombes; Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts. Clitnish Journal of cal Cancer Research 2013, 110, 375-383, 10.1038/bjc.2013.743.6, 23, 88-96, 10.1158/1078-0432.CCR-16-0825.
  19. Nicola Aceto; Fluctuating numbers of circulating tumor cells in cancer patients and the meaning of zero counts.. Qi Wang; Lanbo Zhao; Lu Han; Xiaoqian Tuo; Sijia Ma; Yiran Wang; Xue Feng; Dongxin Liang; Chao Sun; Qing Wang; Qing Song; Qiling Li; The Discordance of Gene Mutations between Circulating Tumor Cells and Primary/Metastatic Tumor. Molecular Therapy - Oncolytarget ics 2019, 10, 2658-2659, 10.18632/oncotarget.26850.5, 21-29, 10.1016/j.omto.2019.08.006.
  20. Marta Vilalta; Marjan Rafat; Amato J. Giaccia; Edward E. Graves; Recruitment of circulating breast cancer cells is stimulated by radiotherapy.. CMarta Pestrin; Francesca Salvianti; Francesca Galardi; Francesca De Luca; Natalie Turner; Luca Malorni; Mario Pazzagli; Angelo Di Leo; Pamela Pinzani; Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Molecull Reports ar Oncology 2014, 8, 402-409, 10.1016/j.celrep.2014.06.011., 9, 749-757, 10.1016/j.molonc.2014.12.001.
  21. Martin, O.A.; Anderson, R.L.; Narayan, K.; MacManus, M.P; Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?. Nat. Rev. Clin. Francesca De Luca; Giada Rotunno; Francesca Salvianti; Francesca Galardi; Marta Pestrin; Stefano Gabellini; Lisa Simi; Irene Mancini; Alessandro Maria Vannucchi; Mario Pazzagli; Angelo Di Leo; Pamela Pinzani; Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncol. target 2017, 14, 32–44.6, 7, 26107-26119, 10.18632/oncotarget.8431.
  22. Vetter, M.; Landin, J.; Szczerba, B.M.; Castro-Giner, F.; Gkountela, S.; Donato, C.; Krol, I.; Scherrer, R.; Balmelli, C.; Malinovska, A.; et al.et al. Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer. BCancer Therapy Committee; An outline of research activities in radiotherapy of the medical research council's (U.K.) cancer therapy Committee. Interenast Cancer Researctional Journal of Radiation Oncology*Biology*Ph 20ysics 1988, 20, 141, 10.1186/s13058-018-1067-y., 14, S17-S19, 10.1016/0360-3016(88)90161-7.
  23. Shaw, J.A.; Guttery, D.S.; Hills, A.; Fernandez-Garcia, D.; Page, K.; Rosales, B.M.; Goddard, K.S.; Hastings, R.K.; Luo, J.; Ogle, O.; et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts. ClM.Z. Gilcrease; Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Breast Dinicseal Cancer Research ses: A Year Book Quarterly 2017, 2, 23, 88-96, 10.1158/1078-0432.CCR-16-0825., 244-246, 10.1016/j.breastdis.2012.06.025.
  24. Qi Wang; Lanbo Zhao; Lu Han; Xiaoqian Tuo; Sijia Ma; Yiran Wang; Xue Feng; Dongxin Liang; Chao Sun; Qing Wang; et al.Qing SongQiling Li The Discordance of Gene Mutations between Circulating Tumor Cells and Primary/Metastatic Tumor. Bahriye Aktas; Sabine Kasimir-Bauer; Volkmar Müller; Wolfgang Janni; Tanja Fehm; D Wallwiener; Klaus Pantel; Mitra Tewes; DETECT Study Group; on behalf of the DETECT study group; Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.. BMolecularC Therapy - Oncolytics Cancer 2019, 6, 15, 21-29, 10.1016/j.omto.2019.08.006.6, 522, 10.1186/s12885-016-2587-4.
  25. Marta Pestrin; Francesca Salvianti; Francesca Galardi; Francesca De Luca; Natalie Turner; Luca Malorni; Mario Pazzagli; Angelo Di Leo; Pamela Pinzani; Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. MS. M. Frisch; H Francis; Disruption of epithelial cell-matrix interactions induces apoptosis. Journalecular Onc of Cell Biology 20 15, 9, 749-757, 10.1016/j.molonc.2014.12.001.994, 124, 619-626, 10.1083/jcb.124.4.619.
  26. De Luca, F.; Rotunno, G.; Salvianti, F.; Galardi, F.; Pestrin, M.; Gabellini, S.; Simi, L.; Mancini, I.; Vannucchi, A.M.; Pazzagli, M.; et al. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget 2016, 7, 26107–26119.Luzzi, K.J.; MacDonald, I.C.; Schmidt, E.E.; Kerkvliet, N.; Morris, V.L.; Chambers, A.F.; Groom, A.C. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. J. Pathol. 1998, 153, 865–873, doi:10.1016/S0002-9440(10)65628-3.
  27. Yu, M.; Bardia, A.; Aceto, N.; Bersani, F.; Madden, M.W.; Donaldson, M.C.; Desai, R.; Zhu, H.; Comaills, V.; Zheng, Z.; et al.et al Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. SMartine Mazel; William Jacot; Klaus Pantel; Kai Bartkowiak; Delphine Topart; Laure Cayrefourcq; Delphine Rossille; Thierry Maudelonde; Thierry Fest; Catherine Alix-Panabières; Frequent expression of PD‐L1 on circulating breast cancer cells. Molecieular Once ology 2014, 345, 216–220, 5, 9, 1773-1782, 10.1016/j.molonc.2015.05.009.
  28. Aktas, B.; Muller, V.; Tewes, M.; Zeitz, J.; Kasimir-Bauer, S.; Loehberg, C.R.; Rack, B.; Schneeweiss, A.; Fehm, T; Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. GyGiulia Brisotto; Eva Biscontin; Elisabetta Rossi; Michela Bulfoni; Aigars Piruska; Simon Spazzapan; Cristina Poggiana; Riccardo Vidotto; Agostino Steffan; Alfonso Colombatti; Wilhelm Huck; Daniela Cesselli; Rita Zamarchi; Matteo Turetta; Fabio Del Ben; Dysmetabolic circulating tumor cells are prognostic in Metastatic Breast Cancer. necoul. Oncol. 2011, 122, 356–360.9, null, 19012211, 10.1101/19012211.
  29. Aktas, B.; Kasimir-Bauer, S.; Muller, V.; Janni, W.; Fehm, T.; Wallwiener, D.; Pantel, K.; Tewes, M.; Group, D.S. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BMC Cancer 2016, 16, 522.LeBleu, V.S.; O'Connell, J.T.; Gonzalez Herrera, K.N.; Wikman, H.; Pantel, K.; Haigis, M.C.; de Carvalho, F.M.; Damascena, A.; Domingos Chinen, L.T.; Rocha, R.M.; et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Cell Biol. 2014, 16, 992–1003, 1001-1015, doi:10.1038/ncb3039.
  30. S. M. Frisch; H Francis; Disruption of epithelial cell-matrix interactions induces apoptosis. JoIrène Baccelli; Andreas Schneeweiss; Sabine Riethdorf; Albrecht Stenzinger; Anja Schillert; Vanessa Vogel; Corinna Klein; Massimo Saini; Tobias Bäuerle; Markus Wallwiener; Tim Holland-Letz; Thomas Höfner; Martin R Sprick; Martina Scharpff; Frederik Marmé; Hans-Peter Sinn; Klaus Pantel; Wilko Weichert; Andreas Trumpp; Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Naturnal of Cell Bio Biotechnology 201994, 3, 3124, 619-626, 10.1083/jcb.124.4.619., 539-544, 10.1038/nbt.2576.
  31. Luzzi, K.J.; MacDonald, I.C.; Schmidt, E.E.; Kerkvliet, N.; Morris, V.L.; Chambers, A.F.; Groom, A.C; Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. PathoAreti Strati; Michail Nikolaou; Vassilis Georgoulias; Evi S. Lianidou; Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients. Cell. s 201998, 153, 865–873., 8, 652, 10.3390/cells8070652.
  32. Martine Mazel; William Jacot; Klaus Pantel; Kai Bartkowiak; Delphine Topart; Laure Cayrefourcq; Delphine Rossille; Thierry Maudelonde; Thierry Fest; Catherine Alix-Panabières; et al. Frequent expression of PD‐L1 on circulating breast cancer cells. Esther A. Reijm; Anieta M. Sieuwerts; Marcel Smid; Joan Bolt-De Vries; Bianca Mostert; Wendy Onstenk; Dieter Peeters; Luc Y. Dirix; Caroline M. Seynaeve; Agnes Jager; Felix E. De Jongh; Paul Hamberg; Anne Van Galen; Jaco Kraan; Maurice P. H. M. Jansen; Jan W. Gratama; John A. Foekens; John W. M. Martens; Els M. J. J. Berns; Stefan Sleijfer; An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.. BMoleculC Car Oncology ncer 2015, 9, 1773-1782, 10.1016/j.molonc.2015.05.009.6, 16, 123, 10.1186/s12885-016-2155-y.
  33. Brisotto, G.; Biscontin, E.; Rossi, E.; Bulfoni, M.; Piruska, A.; Spazzapan, S.; Poggiana, C.; Vidotto, R.; Steffan, A.; Colombatti, A.; et al.et al Dysmetabolic circulating tumor cells are prognostic in Metastatic Breast Cancer. medRxMaren Bredemeier; Philippos Edimiris; Pawel Mach; Mikael Kubista; Robert Sjoback; Marie Jindrichova; Eva Rohlova; Vendula Novosadova; Katarina Kolostova; Siegfried Hauch; Bahriye Aktas; Mitra Tewes; R. Kimmig; Sabine Kasimir-Bauer; Abstract 502: Gene expression signatures in circulating tumor cells are prognostic for metastatic lesions in breast cancer patients and correlate with response to therapy. Clinical Triv als 2019, null, null.6, 76, 502-502, 10.1158/1538-7445.am2016-502.
  34. LeBleu, V.S.; O’Connell, J.T.; Gonzalez Herrera, K.N.; Wikman, H.; Pantel, K.; Haigis, M.C.; de Carvalho, F.M.; Damascena, A.; Domingos Chinen, L.T.; Rocha, R.M.; et al.et al PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. NKristina E. Aaltonen; Vendula Novosadova; Pär-Ola Bendahl; Cecilia Graffman; Anna-Maria Larsson; Lisa Rydén; Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. Oncotarget. Cell Biol. 2014, 16, 992–1003.7, 8, 45544-45565, 10.18632/oncotarget.17271.
  35. Baccelli, I.; Schneeweiss, A.; Riethdorf, S.; Stenzinger, A.; Schillert, A.; Vogel, V.; Klein, C.; Saini, M.; Bauerle, T.; Wallwiener, M.; et al.et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. NatAvisnata Das; Jamal Joudeh; Kristi L. Peters; Joshua E. Allen; Siyang Zheng; David T. Dicker; Zhaohai Yang; Wafik S. El-Deiry; Abstract 3413: A population of metastatic colorectal cancer (mCRC) patients with radiologically proven liver metastasis and EpCAM expressing primary tumors show low circulating tumor cell counts by Veridex Cellsearch. Tumore Biotechno Biology 2013, 31, 539-544, 10.1038/nbt.2576.2, 72, 3413-3413, 10.1158/1538-7445.am2012-3413.
  36. Areti Strati; Michail Nikolaou; Vassilis Georgoulias; Evi S. Lianidou; Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients. CVeena Padmanaban; Ilona Krol; Yasir Suhail; Barbara M. Szczerba; Nicola Aceto; Joel S. Bader; Andrew J. Ewald; E-cadherin is required for metastasis in multiple models of breast cancer.. Naturells 2019, 8, 652, 10.3390/cells8070652., 573, 439-444, 10.1038/s41586-019-1526-3.
  37. Reijm, E.A.; Sieuwerts, A.M.; Smid, M.; Vries, J.B.; Mostert, B.; Onstenk, W.; Peeters, D.; Dirix, L.Y.; Seynaeve, C.M.; Jager, A.; et al.et al. An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.. BMC CYadi Wu; Binhua P. Zhou; Epithelial–Mesenchymal Transition in Development and Diseases. Advanced Str uctural Safety Studies 2016, 16, 123, 10.1186/s12885-016-2155-y.0, null, 187-211, 10.1007/978-1-4419-6615-5_9.
  38. Bredemeier, M.; Edimiris, P.; Mach, P.; Kubista, M.; Sjoback, R.; Rohlova, E.; Kolostova, K.; Hauch, S.; Aktas, B.; Tewes, M.; et al.et al. Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer. CliniMohini Singh; Nicolas Yelle; Chitra Venugopal; Sheila K. Singh; EMT: Mechanisms and therapeutic implications. Pharmacaol Chemiogy & Therapeuticstry 2017, 63, 1585-1593, 10.1373/clinchem.2016.269605.8, 182, 80-94, 10.1016/j.pharmthera.2017.08.009.
  39. Kristina E. Aaltonen; Vendula Novosadova; Pär-Ola Bendahl; Cecilia Graffman; Anna-Maria Larsson; Lisa Rydén; Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. Fei Liu; Li-Na Gu; Bao-En Shan; Cui-Zhi Geng; Meixiang Sang; Biomarkers for EMT and MET in breast cancer: An update. Oncolotarggy Let ters 2017, 8, 45544-45565, 10.18632/oncotarget.17271.6, 12, 4869-4876, 10.3892/ol.2016.5369.
  40. de Wit, S.; Manicone, M.; Rossi, E.; Lampignano, R.; Yang, L.; Zill, B.; Rengel-Puertas, A.; Ouhlen, M.; Crespo, M.; Berghuis, A.M.S.; et al. EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate and breast cancer patients. Oncotarget 2018, 9, 35705–35716.Bill, R.; Christofori, G. The relevance of EMT in breast cancer metastasis: Correlation or causality? FEBS Lett 2015, 589, 1577–1587, doi:10.1016/j.febslet.2015.05.002.
  41. Padmanaban, V.; Krol, I.; Suhail, Y.; Szczerba, B.M.; Aceto, N.; Bader, J.S.; Ewald, A.J. E-cadherin is required for metastasis in multiple models of breast cancer. Nature 2019, 573, 439–444.Skovierova, H.; Okajcekova, T.; Strnadel, J.; Vidomanova, E.; Halasova, E. Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review). Int J. Mol. Med. 2018, 41, 1187–1200, doi:10.3892/ijmm.2017.3320.
  42. Thiery, J.P.; Acloque, H.; Huang, R.Y.; Nieto, M.A; Epithelial-mesenchymal transitions in development and disease. CHaiyan Zhu; Hui Luo; Wenwen Zhang; Zhaojun Shen; Xiaoli Hu; Xueqiong Zhu; Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design, Devell opment and Therapy 2010, 6, 139, 871–890.0, 1885-1895, 10.2147/DDDT.S106412.
  43. Mohini Singh; Nicolas Yelle; Chitra Venugopal; Sheila K. Singh; EMT: Mechanisms and therapeutic implications. PharmacoJing Yang; Sendurai A. Mani; Joana Liu Donaher; Sridhar Ramaswamy; Raphael Itzykson; Christophe Côme; Pierre Savagner; Inna Gitelman; Andrea Richardson; Robert A Weinberg; Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis. Cellogy & Therapeutics 20018, 4, 1182, 80-94, 10.1016/j.pharmthera.2017.08.009.7, 927-939, 10.1016/j.cell.2004.06.006.
  44. Zeisberg, M.; Neilson, E.G; Biomarkers for epithelial-mesenchymal transitions. J. S. Spaderna; O. Schmalhofer; M. Wahlbuhl; A Dimmler; K. Bauer; Aneesa Sultan; F. Hlubek; A. Jung; D. Strand; A. Eger; Thomas Kirchner; J. Behrens; Thomas Brabletz; Sami Sarfaraz; Vaqar M. Adhami; Deeba N. Syed; Farrukh Afaq; Hasan Mukhtar; The Transcriptional Repressor ZEB1 Promotes Metastasis and Loss of Cell Polarity in Cancer. Clian. Invest. cer Research 20019, 119, 1429–1437.8, 68, 537-544, 10.1158/0008-5472.can-07-5682.
  45. Ruben Bill; Gerhard Christofori; The relevance of EMT in breast cancer metastasis: Correlation or causality?. FEBS LeAngela M. Krebs; Julia Mitschke; María Lasierra Losada; Otto Schmalhofer; Melanie Boerries; Hauke Busch; Martin Böttcher; Dimitrios Mougiakakos; Wilfried Reichardt; Peter Bronsert; Valerie G. Brunton; Christian Pilarsky; Thomas H. Winkler; Simone Brabletz; Marc P. Stemmler; Thomas Brabletz; The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Natturers 2015, 587, 19, 1577-1587, 10.1016/j.febslet.2015.05.002., 518-529, 10.1038/ncb3513.
  46. Henrieta Skovierova; Terézia Okajčeková; Ján Strnádel; Eva Vidomanová; Erika Halašová; Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review). InYoshimi Takai; Pastushenko I; Brisebarre A; Sifrim A; Fioramonti M; Revenco T; Boumahdi S; Van Keymeulen A; Brown D; Moers V; Lemaire S; De Clercq S; Minguijón E; Balsat C; Sokolow Y; Dubois C; De Cock F; Scozzaro S; Sopena F; LanaS A; D'haene N; Salmon I; Marine Jc; Voet T; Sotiropoulou Pa; Blanpain C; Faculty of 1000 evaluation for Identification of the tumour transition states occurring during EMT.. F1000 - Postern-publicational Journal of Molecular Medicin peer review of the biomedical literature 2018, 41, 1187-1200, 10.3892/ijmm.2017.3320., 556, , 10.3410/f.733066772.793546632.
  47. Lamouille, S.; Xu, J.; Derynck, R; Molecular mechanisms of epithelial-mesenchymal transition. NMohit Kumar Jolly; Satyendra Tripathi; Dongya Jia; Steven M. Mooney; Muge Celiktas; Samir M. Hanash; Sendurai A. Mani; Kenneth J. Pienta; Eshel Ben-Jacob; Herbert Levine; Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget. Rev. Mol. Cell Biol. 2014, 15, 178–196.6, 7, 27067-27084, 10.18632/oncotarget.8166.
  48. Jing Yang; Sendurai A Mani; Joana Liu Donaher; Sridhar Ramaswamy; Raphael A Itzykson; Christophe Come; Pierre Savagner; Inna Gitelman; Andrea Richardson; Robert A Weinberg; et al. Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis. Elizabeth Williams; Dingcheng Gao; Andrew Redfern; Erik Walter Thompson; Controversies around epithelial-mesenchymal plasticity in cancer metastasis.. Nature Reviews Cancell r 2004, 19, 117, 927-939, 10.1016/j.cell.2004.06.006 [doi] S0092867404005768 [pii].9, 716-732, 10.1038/s41568-019-0213-x.
  49. Spaderna, S.; Schmalhofer, O.; Wahlbuhl, M.; Dimmler, A.; Bauer, K.; Sultan, A.; Hlubek, F.; Jung, A.; Strand, D.; Eger, A.; et al.et al The Transcriptional Repressor ZEB1 Promotes Metastasis and Loss of Cell Polarity in Cancer. Arthur W. Lambert; Diwakar Pattabiraman; Robert A. Weinberg; Emerging Biological Principles of Metastasis.. Cancer Research ll 2008, 17, 168, 537-544, 10.1158/0008-5472.can-07-5682., 670-691, 10.1016/j.cell.2016.11.037.
  50. Krebs, A.M.; Mitschke, J.; Lasierra Losada, M.; Schmalhofer, O.; Boerries, M.; Busch, H.; Boettcher, M.; Mougiakakos, D.; Reichardt, W.; Bronsert, P.; et al.et al The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nature Xiao-Jun Tian; Hang Zhang; Jianhua Xing; Coupled Reversible and Irreversible Bistable Switches Underlying TGF-?-induced Epithelial to Mesenchymal Transition. J. 2017, 3, 19, 518-529, 10.1038/ncb3513.05, 1079–1089, 10.1016/j.bpj.2013.07.011.
  51. Pastushenko, I.; Brisebarre, A.; Sifrim, A.; Fioramonti, M.; Revenco, T.; Boumahdi, S.; Van Keymeulen, A.; Brown, D.; Moers, V.; Lemaire, S.; et al.et al Identification of the tumour transition states occurring during EMT. Nature Mohit Kumar Jolly; Marcelo Boareto; Bin Huang; Dongya Jia; Mingyang Lu; José N. Onuchic; Herbert Levine; Eshel Ben Jacob; Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Oncol. 2018, 5, 556, 463-468., 155, 10.3389/fonc.2015.00155.
  52. Mohit Kumar Jolly; Satyendra Tripathi; Dongya Jia; Steven M. Mooney; Muge Celiktas; Samir M. Hanash; Sendurai A. Mani; Kenneth J. Pienta; Eshel Ben-Jacob; Herbert Levine; et al. Stability of the hybrid epithelial/mesenchymal phenotype. Aigner, K.; Dampier, B.; Descovich, L.; Mikula, M.; Sultan, A.; Schreiber, M.; Mikulits, W.; Brabletz, T.; Strand, D.; Obrist, P., et al.; et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncotargenet 2016, 7, 27067-27084, 10.18632/oncotarget.8166.07, 26, 6979–6988, 10.1038/sj.onc.1210508.
  53. Elizabeth Williams; Dingcheng Gao; Andrew Redfern; Erik Walter Thompson; Controversies around epithelial-mesenchymal plasticity in cancer metastasis. Nature RevYu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.; Shah, A.M., et al.; et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Sciews Cancer 2019, 13, 339, 716-732, 10.1038/s41568-019-0213-x., 580–584, 10.1126/science.1228522.
  54. Arthur W. Lambert; Diwakar Pattabiraman; Robert A. Weinberg; Emerging Biological Principles of Metastasis. CMasao Saitoh; Involvement of partial EMT in cancer progression. The Journall of Biochemistry 2017, 8, 168, 670-691, 10.1016/j.cell.2016.11.037.4, 257-264, 10.1093/jb/mvy047.
  55. Tian, X.J.; Zhang, H.; Xing, J; Coupled reversible and irreversible bistable switches underlying TGFbeta-induced epithelial to mesenchymal transition. Michela Bulfoni; Lorenzo Gerratana; Fabio Del Ben; Stefania Marzinotto; Marisa Sorrentino; Matteo Turetta; Giacinto Scoles; Barbara Toffoletto; Miriam Isola; Carlo Alberto Beltrami; Carla Di Loreto; Paolo Madeddu; F. Puglisi; Daniela Cesselli; In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. Biophyreas. J. t Cancer Research 2013, 6, 105, 1079–1089.8, 30, 10.1186/s13058-016-0687-3.
  56. Jolly, M.K.; Boareto, M.; Huang, B.; Jia, D.; Lu, M.; Ben-Jacob, E.; Onuchic, J.N.; Levine, H; Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis. FroMichal Mego; Marian Karaba; Gabriel Minarik; Juraj Benca; Jurisova Silvia; Tatiana Sedlackova; Denisa Manasova; Katarina Kalavska; Daniel Pindak; Massimo Cristofanilli; James M. Reuben; Jozef Mardiak; Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.. Anticancers in Oncology Research 2015, 5, 155, 10.3389/fonc.2015.00155.9, 39, 1829-1837, 10.21873/anticanres.13290.
  57. Aigner, K.; Dampier, B.; Descovich, L.; Mikula, M.; Sultan, A.; Schreiber, M.; Mikulits, W.; Brabletz, T.; Strand, D.; Obrist, P.; et al.et al The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. OXiao Liu; Junjian Li; Bruno Loureiro Cadilha; Anamarija Markota; Cornelia Voigt; Zhe Huang; Peter Ping Lin; Daisy D. Wang; Juncheng Dai; Gisela Kranz; Anna Krandick; Darko Libl; Horst Zitzelsberger; Isabella Zagorski; Herbert Braselmann; Min Pan; Sibo Zhu; Yuanchi Huang; Sebastian Niedermeyer; Christoph A. Reichel; Bernd Uhl; Daria Briukhovetska; Javier Suárez; Sebastian Kobold; Olivier Gires; Hongxia Wang; Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Sciencogen Advance s 2007, 26, 6979–6988, 19, 5, eaav4275, 10.1126/sciadv.aav4275.
  58. Yu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.; Shah, A.M.; et al.et al Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. SMaria A. Papadaki; Giannis Stoupis; Panayiotis A. Theodoropoulos; Dimitris Mavroudis; Vassilis Georgoulias; Sofia Agelaki; Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. Molecieular Cance r Therapeutics 2013, 339, 580–584.8, 18, 437-447, 10.1158/1535-7163.mct-18-0584.
  59. Masao Saitoh; Involvement of partial EMT in cancer progression. ThEvgeniya V Kaigorodova; Olga Savelieva; Liubov A. Tashireva; Natalia A. Tarabanovskaya; Elena I. Simolina; Evgeny V. Denisov; Elena M. Slonimskaya; Evgeny Choynzonov; Vladimir M. Perelmuter; Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer. Mole Jocurnal of Biochemilestry 2018, 164, 257-264, 10.1093/jb/mvy047., 23, 727, 10.3390/molecules23040727.
  60. Bulfoni, M.; Gerratana, L.; Del Ben, F.; Marzinotto, S.; Sorrentino, M.; Turetta, M.; Scoles, G.; Toffoletto, B.; Isola, M.; Beltrami, C.A.; et al.et al. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. Breast Xiuwen Guan; Fei Ma; Chunxiao Li; Shiyang Wu; Shangying Hu; Jiefen Huang; Xiaoying Sun; Jiayu Wang; Yang Luo; Ruigang Cai; Ying Fan; Qiao Li; Shanshan Chen; Pin Zhang; Qing Li; Binghe Xu; The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer ReCommunications. 2016, 18, 30.9, 39, 1, 10.1186/s40880-018-0346-4.
  61. Michal Mego; Marian Karaba; Gabriel Minarik; Juraj Benca; Jurisova Silvia; Tatiana Sedlackova; Denisa Manasova; Katarina Kalavska; Daniel Pindak; Massimo Cristofanilli; et al.James M. ReubenJozef Mardiak Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer. AnChun Wang; Zhaomei Mu; Inna Chervoneva; Laura Austin; Zhong Ye; Giovanna Rossi; Juan P. Palazzo; Carl Sun; Maysa Abu-Khalaf; Ronald E. Myers; Zhu Zhu; Yanna Ba; Bingshan Li; Lifang Hou; Massimo Cristofanilli; Hushan Yang; Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breastic Cancer Research and Treatment 2019, 39, 1829-1837, 10.21873/anticanres.13290.6, 161, 83-94, 10.1007/s10549-016-4026-2.
  62. Liu, X.; Li, J.; Cadilha, B.L.; Markota, A.; Voigt, C.; Huang, Z.; Lin, P.P.; Wang, D.D.; Dai, J.; Kranz, G.; et al.et al Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. SAleksandra Markiewicz; Justyna Topa; Anna Nagel; Jarosław Skokowski; Barbara Seroczynska; Tomasz Stokowy; Marzena Welnicka-Jaskiewicz; Anna J. Zaczek; Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients. Canci. Adv. ers 2019, 5, eaav4275., 11, 59, 10.3390/cancers11010059.
  63. Maria A. Papadaki; Giannis Stoupis; Panayiotis A. Theodoropoulos; Dimitris Mavroudis; Vassilis Georgoulias; Sofia Agelaki; Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. MoNicola Aceto; Aditya Bardia; David T. Miyamoto; Maria C. Donaldson; Ben S. Wittner; Joel A. Spencer; Min Yu; Adam Pely; Amanda Engstrom; Huili Zhu; et al.Brian W. BranniganRavi KapurShannon L. StottToshi ShiodaSridhar RamaswamyDavid T. TingCharles P. LinMehmet TonerDaniel A. HaberShyamala Maheswaran Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Celecular Cancer Therapeutics 2018, 4, 158, 437-447, 10.1158/1535-7163.mct-18-0584., 1110-1122, 10.1016/j.cell.2014.07.013.
  64. Evgeniya V Kaigorodova; Olga Savelieva; Liubov A. Tashireva; Natalia A. Tarabanovskaya; Elena I. Simolina; Evgeny V. Denisov; Elena M. Slonimskaya; Evgeny Choynzonov; Vladimir M. Perelmuter; Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer. MoCheung, K.J.; Padmanaban, V.; Silvestri, V.; Schipper, K.; Cohen, J.D.; Fairchild, A.N.; Gorin, M.A.; Verdone, J.E.; Pienta, K.J.; Bader, J.S.; et al.et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Natle. Acad. Scules i. USA 2018, 2, 113, 727, 10.3390/molecules23040727., E854-863, 10.3410/f.726113234.793550585.
  65. Guan, X.; Ma, F.; Li, C.; Wu, S.; Hu, S.; Huang, J.; Sun, X.; Wang, J.; Luo, Y.; Cai, R; et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Nicola Aceto; Mehmet Toner; Shyamala Maheswaran; Daniel A. Haber; En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition. Trends in Cancer Commun. (Lond) 2019, 39, 1.5, 1, 44-52, 10.1016/j.trecan.2015.07.006.
  66. Wang, C.; Mu, Z.; Chervoneva, I.; Austin, L.; Ye, Z.; Rossi, G.; Palazzo, J.P.; Sun, C.; Abu-Khalaf, M.; Myers, R.E.; et al.et al Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Sofia Gkountela; Francesc Castro-Giner; Barbara Maria Szczerba; Marcus Vetter; Julia Landin; Ramona Scherrer; Ilona Krol; Manuel C. Scheidmann; Christian Beisel; Christian U. Stirnimann; Christian Kurzeder; Viola Heinzelmann-Schwarz; Christoph Rochlitz; Walter Paul Weber; Nicola Aceto; Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding. Cancer Res. Treat. ll 2017, 9, 1761, 83-94, 10.1007/s10549-016-4026-2., 98-112.e14, 10.1016/j.cell.2018.11.046.
  67. Aleksandra Markiewicz; Justyna Topa; Anna Nagel; Jarosław Skokowski; Barbara Seroczynska; Tomasz Stokowy; Marzena Welnicka-Jaskiewicz; Anna J. Zaczek; Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients. Xia Liu; Rokana Taftaf; Madoka Kawaguchi; Ya-Fang Chang; Wenjing Chen; David Entenberg; Youbin Zhang; Lorenzo Gerratana; Simo Huang; Dhwani B. Patel; Elizabeth Tsui; Valery Adorno-Cruz; Steven M Chirieleison; Yue Cao; Allison S. Harney; Shivani Patel; Antonia Patsialou; Yang Shen; Stefanie Avril; Hannah L. Gilmore; Justin D. Lathia; Derek W. Abbott; Massimo Cristofanilli; John S. Condeelis; Huiping Liu; Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Cancer Dis covery 2019, 11, 59, 10.3390/cancers11010059.8, 9, 96-113, 10.1158/2159-8290.cd-18-0065.
  68. Aceto, N.; Bardia, A.; Miyamoto, D.T.; Donaldson, M.C.; Wittner, B.S.; Spencer, J.A.; Yu, M.; Pely, A.; Engstrom, A.; Zhu, H.; et al.et al Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Mario Giuliano; Anum Shaikh; Hin Ching Lo; Grazia Arpino; Sabino De Placido; Xiang H. Zhang; Massimo Cristofanilli; Rachel Schiff; Meghana V. Trivedi; Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. Cancell r Research 2014, 158, 78, 1110-1122., 845-852, 10.1158/0008-5472.can-17-2748.
  69. Cheung, K.J.; Padmanaban, V.; Silvestri, V.; Schipper, K.; Cohen, J.D.; Fairchild, A.N.; Gorin, M.A.; Verdone, J.E.; Pienta, K.J.; Bader, J.S.; et al.et al Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. PrQicheng Zhao; Monica Barclay; J.G.W. Hilkens; Xiuli Guo; Hannah Barrow; Jonathan M. Rhodes; Lu-Gang Yu; Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Molec. Natl. Acad. Sci. USA ular Cancer 2016, 113, E854-E863.0, 9, 154-154, 10.1186/1476-4598-9-154.
  70. Nicola Aceto; Mehmet Toner; Shyamala Maheswaran; Daniel A. Haber; En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition. TDeva Sharma; Beth Bouchard; Chris E Holmes; Kathleen E. Brummel-Ziedins; Platelets in Tumor Progression: A Host Factor That Offers Multiple Potential Targets in the Treatment of Cancer. Jourends in Canceal of Cellular Physiology 2015, 1, 44-52, 10.1016/j.trecan.2015.07.006.4, 229, 1005-1015, 10.1002/jcp.24539.
  71. Gkountela, S.; Castro-Giner, F.; Szczerba, B.M.; Vetter, M.; Landin, J.; Scherrer, R.; Krol, I.; Scheidmann, M.C.; Beisel, C.; Stirnimann, C.U.; et al.et al Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding. CDan G. Duda; Annique M. M. J. Duyverman; Mitsutomo Kohno; Matija Snuderl; Ernst J. A. Steller; Dai Fukumura; Rakesh K. Jain; Malignant cells facilitate lung metastasis by bringing their own soil.. Proceedings of the Nationall Academy of Sciences 2019, 0, 1076, 98-112.e14, 10.1016/j.cell.2018.11.046., 21677-82, 10.1073/pnas.1016234107.
  72. Liu, X.; Taftaf, R.; Kawaguchi, M.; Chang, Y.F.; Chen, W.; Entenberg, D.; Zhang, Y.; Gerratana, L.; Huang, S.; Patel, D.B.; et al.et al Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. CSam Au; Brian D. Storey; John C. Moore; Qin Tang; Yeng-Long Chen; Sarah Javaid; A. Fatih Sarioglu; Ryan Sullivan; Marissa W. Madden; Ryan O’Keefe; James E Haber; Shyamala Maheswaran; David M. Langenau; Shannon L. Stott; Mehmet Toner; Clusters of circulating tumor cells traverse capillary-sized vessels.. Proceedings of the Nationcer Dial Academy of Sciencescov. 2019, 9, 96-113, 10.1158/2159-8290.cd-18-0065.6, 113, 4947-52, 10.1073/pnas.1524448113.
  73. Giuliano, M.; Shaikh, A.; Lo, H.C.; Arpino, G.; De Placido, S.; Zhang, X.H.; Cristofanilli, M.; Schiff, R.; Trivedi, M.V; Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. B. Jäger; B. Rack; Christian Schindlbeck; R. Lorenz; H. Tesch; A. Schneeweiss; W. Lichtenegger; M.W. Beckmann; K. Pantel; Wolfgang Janni; 301 Survival in Early Breast Cancer Patients is Influenced by Circulating Tumor Cells. European Journal of Cancer Research 2018, 72, 48, 845-852, 10.1158/0008-5472.can-17-2748., S130, 10.1016/s0959-8049(12)70367-2.
  74. Zhao, Q.; Barclay, M.; Hilkens, J.; Guo, X.; Barrow, H.; Rhodes, J.M.; Yu, L.G; Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. MFrançois-Clément Bidard; S. Michiels; Sabine Riethdorf; Volkmar Mueller; Laura J. Esserman; Anthony Lucci; Bjørn Naume; Jun Horiguchi; Rafael Gisbert-Criado; Stefan Sleijfer; Masakazu Toi; José A. García-Sáenz; Andreas Hartkopf; Daniele Generali; Françoise Rothé; Jeffrey Smerage; Laura Muinelo-Romay; Justin Stebbing; Patrice Viens; Mark Jesus M. Magbanua; Carolyn Hall; Olav Engebraaten; Daisuke Takata; Jose Vidal-Martinez; Wendy Onstenk; Noriyoshi Fujisawa; Eduardo Diaz-Rubio; Florin-Andrei Taran; Maria Rosa Cappelletti; M. Ignatiadis; Charlotte Proudhon; Denise M Wolf; Jessica B Bauldry; Elin Borgen; Rin Nagaoka; Vicente Carañana; Jaco Kraan; Marisa Maestro; Sara Yvonne Brucker; Karsten Weber; F. Reyal; Dominic Amara; Mandar Karhade; Randi R Mathiesen; Hideaki Tokiniwa; A. Llombart; Alessandra Meddis; Paul Blanche; Koenraad D'hollander; P. Cottu; John W Park; Sibylle Loibl; Aurélien Latouche; Jean-Yves Pierga; Klaus Pantel; Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. JNCI: Journalecular of the National Cancer Institute 2010, 9, 154, 10.1186/1476-4598-9-154.8, 110, 560-567, 10.1093/jnci/djy018.
  75. Sharma, D.; Brummel-Ziedins, K.E.; Bouchard, B.A.; Holmes, C.E; Platelets in Tumor Progression: A Host Factor That Offers Multiple Potential Targets in the Treatment of Cancer. JourAnthony Lucci; Carolyn S Hall; Ashutosh K Lodhi; Anirban Bhattacharyya; Amber E Anderson; Lianchun Xiao; Isabelle Bedrosian; Henry M Kuerer; Savitri Krishnamurthy; Circulating tumour cells in non-metastatic breast cancer: a prospective study. The Lanal of Ccellular Physit Oncology 2014, 229, 1005-1015, 10.1002/jcp.24539.2, 13, 688-695, 10.1016/s1470-2045(12)70209-7.
  76. Duda, D.G.; Duyverman, A.M.; Kohno, M.; Snuderl, M.; Steller, E.J.; Fukumura, D.; Jain, R.K; Malignant cells facilitate lung metastasis by bringing their own soil.. PBrigitte Rack; Christian Schindlbeck; Julia Jückstock; Ulrich Andergassen; Philip Hepp; Thomas Zwingers; Thomas W. P. Friedl; Ralf Lorenz; Hans Tesch; Peter A. Fasching; Tanja Fehm; Andreas Schneeweiss; Werner Lichtenegger; Matthias W. Beckmann; Klaus Friese; Klaus Pantel; Wolfgang Janni; SUCCESS Study Group; Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.. JNCI: Jouroceedingsal of the National Academy of SciCancer Institutences 2010, 4, 107, 21677-82, 10.1073/pnas.1016234107.6, , 10.1093/jnci/dju066.
  77. Au, S.H.; Storey, B.D.; Moore, J.C.; Tang, Q.; Chen, Y.L.; Javaid, S.; Sarioglu, A.F.; Sullivan, R.; Madden, M.W.; O’Keefe, R; et al. Clusters of circulating tumor cells traverse capillary-sized vessels.. ProceedWolfgang Janni; Brigitte Rack; L. W. M. M. Terstappen; Jean-Yves Pierga; Florin-Andrei Taran; Prof. Dr. Med. Tanja Fehm; Carolyn Hall; Marco R De Groot; François-Clément Bidard; Thomas W.P. Friedl; Peter A. Fasching; Sara Brucker; Klaus Pantel; Anthony Lucci; Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clings of the National Academy of Sciences cal Cancer Research 2016, 113, 4947-4952, 10.1073/pnas.1524448113., 22, 2583-2593, 10.1158/1078-0432.ccr-15-1603.
  78. Thery, L.; Meddis, A.; Cabel, L.; Proudhon, C.; Latouche, A.; Pierga, J.Y.; Bidard, F.C; Circulating Tumor Cells in Early Breast Cancer. JNCIMarta Pestrin; Silvia Bessi; F. Puglisi; Alessandro M. Minisini; Giovanna Masci; Nicola Battelli; Alberto Ravaioli; Lorenzo Gianni; Roberta Di Marsico; Carlo Tondini; Stefania Gori; Charles R. Coombes; Justin Stebbing; Laura Biganzoli; Marc Buyse; Angelo Di Leo; Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer SpResectr. arch and Treatment 2019, 2, 13, pkz026.4, 283-289, 10.1007/s10549-012-2045-1.
  79. Bidard, F.C.; Michiels, S.; Riethdorf, S.; Mueller, V.; Esserman, L.J.; Lucci, A.; Naume, B.; Horiguchi, J.; Gisbert-Criado, R.; Sleijfer, S; et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Joseph A. Sparano; Anne O’Neill; Katherine Alpaugh; Antonio C. Wolff; Donald W. Northfelt; Chau T. Dang; George W. Sledge; Kathy D. Miller; Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JNCI:AMA Journal of the National Cancer Institute Oncology 2018, 110, 560-567, 10.1093/jnci/djy018., 4, 1700-1706, 10.1001/jamaoncol.2018.2574.
  80. Lucci, A.; Hall, C.S.; Lodhi, A.K.; Bhattacharyya, A.; Anderson, A.E.; Xiao, L.; Bedrosian, I.; Kuerer, H.M.; Krishnamurthy, S; Circulating tumour cells in non-metastatic breast cancer: a prospective study. TheW. Janni; Brigitte Rack; Peter A. Fasching; Lothar Haeberle; Hans Tesch; Ralf Lorenz; Fabienne Schochter; Marie Tzschaschel; Amelie De Gregorio; Prof. Dr. Med. Tanja Fehm; et al.Volkmar MüllerAndreas SchneeweissWerner LichteneggerMatthias W. BeckmannC. ScholzKlaus PantelThomas W.P. Friedl Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial. Journal of LaClincetical Oncology 2012, 18, 3, 688-695, 10.1016/s1470-2045(12)70209-7.6, 515-515, 10.1200/jco.2018.36.15_suppl.515.
  81. Rack, B.; Schindlbeck, C.; Juckstock, J.; Andergassen, U.; Hepp, P.; Zwingers, T.; Friedl, T.W.; Lorenz, R.; Tesch, H.; Fasching, P.A; et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.. JTrapp, E.; Janni, W.; Schindlbeck, C.; Juckstock, J.; Andergassen, U.; de Gregorio, A.; Alunni-Fabbroni, M.; Tzschaschel, M.; Polasik, A.; Koch, J.G.; et al.et al. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. NCI: Journal of the Nationaltl. Cancer Institute . 2014, 9, 11106, none., 380–387, 10.1093/jnci/djy152.
  82. Janni, W.J.; Rack, B.; Terstappen, L.W.; Pierga, J.Y.; Taran, F.A.; Fehm, T.; Hall, C.; de Groot, M.R.; Bidard, F.C.; Friedl, T.W; et al. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. CliChelain Goodman; Brandon-Luke L. Seagle; Thomas W. P. Friedl; Brigitte Rack; Krisztian Lato; Visnja Fink; Massimo Cristofanilli; Eric D. Donnelly; Wolfgang Janni; Shohreh Shahabi; et al.Jonathan B. Strauss Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer.. JAMA Onical Cancer Research ology 2016, 22, 2583-2593, 10.1158/1078-0432.ccr-15-1603.8, 4, e180163, 10.1001/jamaoncol.2018.0163.
  83. Ignatiadis, M.; Rothe, F.; Chaboteaux, C.; Durbecq, V.; Rouas, G.; Criscitiello, C.; Metallo, J.; Kheddoumi, N.; Singhal, S.K.; Michiels, S.; et al. HER2-positive circulating tumor cells in breast cancer. PLoS ONE 2011, 6, e15624.Ignatiadis, M.; Litiere, S.; Rothe, F.; Riethdorf, S.; Proudhon, C.; Fehm, T.; Aalders, K.; Forstbauer, H.; Fasching, P.A.; Brain, E.; et al. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. Oncol. 2018, 29, 1777–1783, doi:10.1093/annonc/mdy211.
  84. Sparano, J.; O’Neill, A.; Alpaugh, K.; Wolff, A.C.; Northfelt, D.W.; Dang, C.T.; Sledge, G.W.; Miller, K.D; Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.. JAMALiling Zhang; Sabine Riethdorf; Gang Wu; Tao Wang; Kunyu Yang; Gang Peng; Jun-Li Liu; Klaus Pantel; Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer. Clinical OCancology er Research 2018, 4, 1700-1706, 10.1001/jamaoncol.2018.2574.2, 18, 5701-5710, 10.1158/1078-0432.ccr-12-1587.
  85. Janni, W.; Rack, B.K.; Fasching, P.A.; Haeberle, L.; Tesch, H.; Lorenz, R.; Schochter, F.; Tzschaschel, M.; Gregorio, A.D.; Fehm, T.N.; et al. Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial. J. Clin. Oncol. 2018, 36, 515.Giordano, A.; Giuliano, M.; Hsu, L.; Handy, B.C.; Ueno, N.T.; Andreopoulou, E.; Alvarez, R.H.; Valero, V.; Hortobagyi, G.N.; Cristofanilli, M. Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. Clin. Oncol. 2010, 28, 1000–1000, doi:10.1200/jco.2010.28.15_suppl.1000.
  86. Trapp, E.; Janni, W.; Schindlbeck, C.; Juckstock, J.; Andergassen, U.; de Gregorio, A.; Alunni-Fabbroni, M.; Tzschaschel, M.; Polasik, A.; Koch, J.G; et al. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. JNG. Thomas Budd; Massimo Cristofanilli; Mathew J. Ellis; Allison Stopeck; Ernest Borden; M. Craig Miller; Jeri Matera; Madeline Repollet; Gerald V. Doyle; Leon W.M.M. Terstappen; Daniel F Hayes; Circulating Tumor Cells versus Imaging--Predicting Overall Survival in Metastatic Breast Cancer. CI: Journal of the Nationinical Cancer InstitutRese arch 20019, 6, 111, 380-387, 10.1093/jnci/djy152.2, 6403-6409, 10.1158/1078-0432.CCR-05-1769.
  87. Goodman, C.R.; Seagle, B.L.; Friedl, T.W.P.; Rack, B.; Lato, K.; Fink, V.; Cristofanilli, M.; Donnelly, E.D.; Janni, W.; Shahabi, S; et al. Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer.. JAMAE. Glatstein; Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. Yearbook of Oncology 20018, 4, e180163, 10.1001/jamaoncol.2018.0163.6, 2006, 91-96, 10.1016/s1040-1741(08)70062-9.
  88. Ignatiadis, M.; Litiere, S.; Rothe, F.; Riethdorf, S.; Proudhon, C.; Fehm, T.; Aalders, K.; Forstbauer, H.; Fasching, P.A.; Brain, E.; et al. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase II trial. Ann. Oncol. 2018, 29, 1777–1783.Banys-Paluchowski, M.; Fehm, T.; Janni, W.; Solomayer, E.F.; Hartkopf, A. Circulating and Disseminated Tumor Cells in Breast Carcinoma: Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019. Geburtshilfe Frauenheilkd 2019, 79, 1320–1327, doi:10.1055/a-1031-1120.
  89. Zhang, L.; Riethdorf, S.; Wu, G.; Wang, T.; Yang, K.; Peng, G.; Liu, J.; Pantel, K; Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer. Bidard, F.-C.; Jacot, W.; Dureau, S.; Brain, E.; Bachelot, T.; Bourgeois, H.; Goncalves, A.; Ladoire, S.; Naman, H.; Dalenc, F.; et al.et al. Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial. Clinical Cancer Research . 2012, 18, 5701-5710, 10.1158/1078-0432.ccr-12-1587.9, 79, GS3-07-GS03-07, 10.1158/1538-7445.sabcs18-gs3-07.
  90. Giordano, A.; Giuliano, M.; Hsu, L.; Handy, B.C.; Ueno, N.T.; Andreopoulou, E.; Alvarez, R.H.; Valero, V.; Hortobagyi, G.N.; Cristofanilli, M; et al. Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. Jeffrey B. Smerage; William E. Barlow; Gabriel N. Hortobagyi; Eric P. Winer; Brian Leyland-Jones; Gordan Srkalovic; Sheela Tejwani; Anne F. Schott; Mark A. O'rourke; Danika L. Lew; Gerald V. Doyle; Julie R. Gralow; Robert B. Livingston; Daniel F Hayes; Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. J.ournal of Clin.ical Oncol. ogy 2010, 4, 328, 1000., 3483-3489, 10.1200/jco.2014.56.2561.
  91. Budd, G.T.; Cristofanilli, M.; Ellis, M.J.; Stopeck, A.; Borden, E.; Miller, M.C.; Matera, J.; Repollet, M.; Doyle, G.V.; Terstappen, L.W; et al. irculating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin.William Jacot; Paul Cottu; Frederique Berger; Coraline Dubot; Laurence Venat-Bouvet; Alain Lortholary; Hugues Bourgeois; Marc Bollet; Veronique Servent; Elisabeth Luporsi; Marc Espié; Severine Guiu; Veronique D’Hondt; Veronique Dieras; Marie-Paule Sablin; Etienne Brain; Souhir Neffati; Jean-Yves Pierga; François-Clément Bidard; Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.. Breast Cancer Res. earch 2006, 19, 212, 6403–6409, , 121, 10.1186/s13058-019-1215-z.
  92. Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W; et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N.A. Polasik; Amelie Schramm; Thomas W.P. Friedl; Brigitte Rack; Elisabeth Trapp; Peter A. Fasching; Florin-Andrei Taran; Andreas Hartkopf; Andreas Schneeweiss; Volkmar Mueller; Bahriye Aktas; Klaus Pantel; Franziska Meier-Stiegen; Pauline Wimberger; W. Janni; Prof. Dr. Med. Tanja Fehm; The DETECT study concept: Individualized therapy of metastatic breast cancer.. Journal of EClingl. J. Med. ical Oncology 2004, 16, 351, 781–791.4, TPS634-TPS634, 10.1200/jco.2016.34.15_suppl.tps634.
  93. Banys-Paluchowski, M.; Fehm, T.; Janni, W.; Solomayer, E.F.; Hartkopf, A; Circulating and Disseminated Tumor Cells in Breast Carcinoma: Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019. GCostanza Paoletti; Jieling Miao; Emily M. Dolce; Elizabeth P. Darga; Madeline I. Repollet; Gerald V. Doyle; Julie R. Gralow; Gabriel N. Hortobagyi; Jeffrey B. Smerage; William E. Barlow; Daniel F. Hayes; Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study.. Clinical Canceburtshilfe Frauen Researcheilkd 2019, 79, 1320–1327., 25, 6089-6097, 10.1158/1078-0432.CCR-19-0208.
  94. Cristofanilli, M.; Pierga, J.Y.; Reuben, J.; Rademaker, A.; Davis, A.A.; Peeters, D.J.; Fehm, T.; Nole, F.; Gisbert-Criado, R.; Mavroudis, D.; et al.et al. Bidard, F.-C.; Jacot, W.; Dureau, S.; Brain, E.; Bachelot, T.; Bourgeois, H.; Goncalves, A.; Ladoire, S.; Naman, H.; Dalenc, F. CaCristofanilli, M.; Pierga, J.Y.; Reuben, J.; Rademaker, A.; Davis, A.A.; Peeters, D.J.; Fehm, T.; Nole, F.; Gisbert-Criado, R.; Mavroudis, D.; et al.et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Rev. Oncerol. ResHematol. 2019, 79, GS3-07-GS03-07., 134, 39–45, 10.1016/j.critrevonc.2018.12.004.
  95. Smerage, J.B.; Barlow, W.E.; Hortobagyi, G.N.; Winer, E.P.; Leyland-Jones, B.; Srkalovic, G.; Tejwani, S.; Schott, A.F.; O’Rourke, M.A.; Lew, D.L; et al. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Journal of Schochter, F.; Friedl, T.W.P.; deGregorio, A.; Krause, S.; Huober, J.; Rack, B.; Janni, W; Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions. Celinical Oncology ls 2014, 32, 3483-3489, 10.1200/jco.2014.56.2561.9, 8, none, 10.3390/cells8111412.
  96. Jacot, W.; Cottu, P.; Berger, F.; Dubot, C.; Venat-Bouvet, L.; Lortholary, A.; Bourgeois, H.; Bollet, M.; Servent, V.; Luporsi, E; et al. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.. BFrançois-Clément Bidard; Tanja Fehm; Michail Ignatiadis; Jeffrey B. Smerage; Catherine Alix-Panabières; Wolfgang Janni; Carlo Messina; Costanza Paoletti; Volkmar Müller; Daniel F. Hayes; Martine Piccart; Jean-Yves Pierga; Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.. Cancer and Meast Cancer Retastasis Reviewsearch 2019, 3, 321, 121, 10.1186/s13058-019-1215-z., 179-88, 10.1007/s10555-012-9398-0.
  97. Polasik, A.; Schramm, A.; Friedl, T.W.P.; Rack, B.K.; Trapp, E.K.; Fasching, P.A.; Taran, F.-A.; Hartkopf, A.D.; Schneeweiss, A.; Mueller, V; et al. The DETECT study concept: Individualized therapy of metastatic breast cancer. Journal of Marta Tellez-Gabriel; Lidia Rodriguez Calleja; Antoine Chalopin; Benjamin Ory; Dominique Heymann; Circulating Tumor Cells: A Review of Non–EpCAM-Based Approaches for Cell Enrichment and Isolation. Clinical OncologChemistry 2016, 34, TPS634., 62, 571-581, 10.1373/clinchem.2015.249706.
  98. Paoletti, C.; Miao, J.; Dolce, E.M.; Darga, E.P.; Repollet, M.I.; Doyle, G.V.; Gralow, J.R.; Hortobagyi, G.N.; Smerage, J.B.; Barlow, W.E; et al. Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. ClFrançoise Farace; C Massard; N Vimond; F Drusch; N Jacques; F Billiot; A Laplanche; Anne Chauchereau; L Lacroix; D Planchard; S Le Moulec; Fabrice André; K Fizazi; J C Soria; P Vielh; A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British Journicalal of Cancer Research 20119, 2, 105, 6089-6097, 10.1158/1078-0432.CCR-19-0208., 847-853, 10.1038/bjc.2011.294.
  99. Cristofanilli, M.; Pierga, J.Y.; Reuben, J.; Rademaker, A.; Davis, A.A.; Peeters, D.J.; Fehm, T.; Nole, F.; Gisbert-Criado, R.; Mavroudis, D; et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Shyamala Maheswaran; Daniel A Haber; Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy.. Cancerit. Rev. Oncol. Hematol. Research 2019, 134, 39–45.5, 75, 2411-5, 10.1158/0008-5472.CAN-15-0145.
  100. Schochter, F.; Friedl, T.W.P.; deGregorio, A.; Krause, S.; Huober, J.; Rack, B.; Janni, W; Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions. CJohannes C. Fischer; Dieter Niederacher; Stefan A. Topp; Ellen Honisch; Sarah Schumacher; Norma Schmitz; Luisa Zacarias Föhrding; Christian Vay; Imke Hoffmann; Nikola S. Kasprowicz; Philip Hepp; Svjetlana Mohrmann; Ulrike Nitz; Antje Stresemann; Thomas Krahn; Tanja Henze; Evelyn Griebsch; Katharina Raba; Jutta M. Rox; Folker Wenzel; Christoph Sproll; Wolfgang Janni; Tanja Fehm; Christoph A. Klein; Wolfram Trudo Knoefel; Nikolas H. Stoecklein; Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proceedings of the Nationall Academy of Sciences 2019, 8, 1412.3, 110, 16580-16585, 10.1073/pnas.1313594110.
  101. Bidard, F.C.; Fehm, T.; Ignatiadis, M.; Smerage, J.B.; Alix-Panabieres, C.; Janni, W.; Messina, C.; Paoletti, C.; Muller, V.; Hayes, D.F; et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.. CancerYoon-Sim Yap; Man Chun Leong; Yong Wei Chua; Kiley Wei Jen Loh; Guek Eng Lee; Elaine Hsuen Lim; Rebecca Dent; Raymond Chee Hui Ng; John Heng-Chi Lim; Garima Singh; Angela Tan; Guofeng Guan; Andrew Wu; Yi Fang Lee; Ali Asgar Bhagat; Darren Wan-Teck Lim; Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform.. PLOS and Metastasis Reviews ONE 2013, 32, 179-88, 10.1007/s10555-012-9398-0.9, 14, e0221305, 10.1371/journal.pone.0221305.
  102. Gabriel, M.T.; Calleja, L.R.; Chalopin, A.; Ory, B.; Heymann, D; Circulating Tumor Cells: A Review of Non–EpCAM-Based Approaches for Cell Enrichment and Isolation. Volkmar Müller; Sabine Riethdorf; Brigitte Rack; Wolfgang Janni; Peter A. Fasching; Erich Solomayer; Bahriye Aktas; Sabine Kasimir-Bauer; Klaus Pantel; Prof. Dr. Med. Tanja Fehm; Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Clianical Chemistry cer Research 2016, 62, 571-581, 10.1373/clinchem.2015.249706.2, 14, R118-R118, 10.1186/bcr3243.
  103. Agerbaek MO, Bang-Christensen SR, Yang MH, Clausen TM, Pereira MA, Sharma S; The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner.. Mette Ø. Agerbæk; Sara R. Bang-Christensen; Ming-Hsin Yang; Thomas M. Clausen; Marina Maria Bento Ayres Pereira; Shreya Sharma; Sisse B. Ditlev; Morten Nielsen; Swati Choudhary; Tobias Gustavsson; Poul H. Sorensen; Tim Meyer; David Propper; Jonathan Shamash; Thor Theander; Alexandra Aicher; Mads Daugaard; Christopher Heeschen; Ali Salanti; The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner.. Nature Communications 2018, 9, 3279, 10.1038/s41467-018-05793-2.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Feedback